Pharmacokinetic Study of Buagafuran Capsules in Participants With Hepatic Impairment and Normal Hepatic Function

Inclusion criteria

• ✓. Voluntarily sign an informed consent form before the start of activities related to this trial, understand the procedures and methods of this trial, and be willing to strictly follow the clinical trial protocol to complete this trial;
• ✓. Participants (including partners) are willing to have no fertility plans from screening to within 6 months after the last administration of the study drug, and voluntarily adopt highly effective contraceptive measures;
• ✓. On the day of signing the informed consent form, the age range is 18 to 70 years old (including both ends), and both males and females are eligible;
• ✓. Male participants should weigh no less than 50 kg, and female participants should weigh no less than 45 kg; Body Mass Index (BMI) should be between 18 and 32 kg/m2 (including both ends), with BMI=weight (kg)/height (m2);
• ✓. Creatinine clearance rate ≥ 60 mL/min;
• ✓. Participants with normal hepatic function must also meet all of the following criteria: a): Weight matching with the hepatic impairment group, with an average weight range of ± 10 kg; b): Age matching with the hepatic impairment group, with an average age range of ± 10 years; c): The number of participants of each gender is similar to that of the hepatic impairment group (mean ± 1 participant/gender);
• ✓. Participants with hepatic impairment must also meet all of the following conditions: a): Chronic hepatic impairment caused by primary hepatic diseases, and hepatic impairment patients with Child Pugh classification of A or B; b):The clinical diagnosis is cirrhosis; c): Individuals who have a stable medication regimen for treating hepatic impairment, complications, and other accompanying diseases for at least 14 days prior to taking the investigational drug, and whose medication does not require adjustment; or those who have not taken medication;

Exclusion criteria